The proteasome inhibitor bortezomib down-regulated CIP2A in a dose- and time-dependent manner in all sensitive hepatocellular carcinoma (HCC) cell lines, whereas no alterations in CIP2A were found in resistant PLC5 cells. Here, CIP2A is linked to hepatocellular carcinoma.